Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADIL
stocks logo

ADIL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.090
-40%
--
--
-0.115
-66.18%
--
--
-0.105
-41.67%
Estimates Revision
The market is revising No Change the revenue expectations for Adial Pharmaceuticals, Inc. (ADIL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.40%.
EPS Estimates for FY2025
Revise Downward
down Image
-19.05%
In Past 3 Month
Stock Price
Go Down
down Image
-6.40%
In Past 3 Month
Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.326
sliders
Low
1.50
Averages
1.50
High
1.50
Current: 0.326
sliders
Low
1.50
Averages
1.50
High
1.50
Maxim
Hold
to
Buy
upgrade
$1.50
2025-09-30
Reason
Maxim
Price Target
$1.50
2025-09-30
upgrade
Hold
to
Buy
Reason
Maxim upgraded Adial Pharmaceuticals to Buy from Hold with a $1.50 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Adial Pharmaceuticals Inc (ADIL.O) is -0.77, compared to its 5-year average forward P/E of -1.66. For a more detailed relative valuation and DCF analysis to assess Adial Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.66
Current PE
-0.77
Overvalued PE
-0.28
Undervalued PE
-3.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.86
Undervalued EV/EBITDA
-2.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
21509.22
Current PS
0.00
Overvalued PS
98863.25
Undervalued PS
-55844.82
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ADIL News & Events

Events Timeline

(ET)
2025-11-26
08:03:30
Adial Pharmaceuticals reveals $2.86 million warrant inducement deal
select
2025-11-14 (ET)
2025-11-14
08:34:27
Adial Pharmaceuticals announces Q3 net loss of $1.8 million, down from $2.2 million a year ago.
select
2025-10-09 (ET)
2025-10-09
08:39:06
Adial Pharmaceuticals Collaborates with Genomind on Precision Medicine Testing
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-26Globenewswire
Adial Pharmaceuticals Enters Warrant Inducement Agreement, Raising $2.86 Million
  • Financing Agreement Reached: Adial Pharmaceuticals has entered into a warrant inducement agreement with an existing institutional investor, enabling the immediate exercise of existing Series C-1 Warrants to raise approximately $2.86 million, enhancing the company's liquidity to support R&D and operations.
  • Warrant Details: The investor will receive new unregistered Series F Warrants to purchase up to 13,823,512 shares of Common Stock at an exercise price of $0.31, which will expire 24 months after shareholder approval, further enhancing the company's capital structure flexibility.
  • Market Reaction Anticipated: This financing is expected to provide Adial with essential funding to advance its research in addiction treatment, particularly for its investigational drug AD04 targeting Alcohol Use Disorder, potentially boosting future market performance.
  • Transaction Timeline: The closing of this transaction is expected around December 1, 2025, subject to customary closing conditions, demonstrating the company's proactive and strategic approach in capital market operations.
[object Object]
Preview
9.5
11-14Newsfilter
Adial Pharmaceuticals Announces Financial Results for Q3 2025 and Offers Business Update

  • Business Update: Adial Pharmaceuticals reported progress towards FDA approval for its lead drug AD04, aimed at treating Alcohol Use Disorder (AUD), following a successful End of Phase 2 meeting with the FDA that provided guidance for the upcoming Phase 3 study.

  • Legislative Support: Recent bipartisan support from the U.S. Senate encourages the expansion of clinical trial endpoints beyond abstinence, aligning with Adial's focus on reducing alcohol consumption and cravings, which reinforces their patient-centered treatment approach.

  • Partnership and Testing: Adial has partnered with Genomind to develop a precision medicine testing solution, completing validation for a genetic test that identifies eligible patients, which is crucial for clinical trials and future commercial use.

  • Financial Overview: As of September 30, 2025, Adial reported $4.6 million in cash, with a net loss of $1.8 million for the quarter, reflecting a decrease in research and development expenses compared to the previous year.

[object Object]
Preview
9.0
10-17Newsfilter
Adial Pharmaceuticals CEO Appeared as a Guest on The Big Biz Show

  • Adial Pharmaceuticals' Media Appearance: Cary Claiborne, CEO of Adial Pharmaceuticals, was featured on the Big Biz Show, a nationally syndicated program, which aired on October 15, 2025, across various platforms including Fox Business and streaming services.

  • Focus on Addiction Treatments: Adial Pharmaceuticals is developing AD04, a drug aimed at treating Alcohol Use Disorder (AUD) and potentially other addictions, which has shown promising results in a recent Phase 3 clinical trial.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Adial Pharmaceuticals Inc (ADIL) stock price today?

The current price of ADIL is 0.3262 USD — it has increased 3.49 % in the last trading day.

arrow icon

What is Adial Pharmaceuticals Inc (ADIL)'s business?

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

arrow icon

What is the price predicton of ADIL Stock?

Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Adial Pharmaceuticals Inc (ADIL)'s revenue for the last quarter?

Adial Pharmaceuticals Inc revenue for the last quarter amounts to -1.76M USD, decreased -20.23 % YoY.

arrow icon

What is Adial Pharmaceuticals Inc (ADIL)'s earnings per share (EPS) for the last quarter?

Adial Pharmaceuticals Inc. EPS for the last quarter amounts to -1833373.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Adial Pharmaceuticals Inc (ADIL)'s fundamentals?

The market is revising No Change the revenue expectations for Adial Pharmaceuticals, Inc. (ADIL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.40%.
arrow icon

How many employees does Adial Pharmaceuticals Inc (ADIL). have?

Adial Pharmaceuticals Inc (ADIL) has 5 emplpoyees as of December 05 2025.

arrow icon

What is Adial Pharmaceuticals Inc (ADIL) market cap?

Today ADIL has the market capitalization of 7.56M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free